SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:9c50c3dd-6929-400e-9e3f-ef22727d85d0"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:9c50c3dd-6929-400e-9e3f-ef22727d85d0" > Discontinuation of ...

  • Saussele, SusanneHeidelberg University,Heidelberg Univ, Dept Haematol & Oncol, Univ Hosp Mannheim, Mannheim, Germany (författare)

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Elsevier,2018

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:9c50c3dd-6929-400e-9e3f-ef22727d85d0
  • https://lup.lub.lu.se/record/9c50c3dd-6929-400e-9e3f-ef22727d85d0URI
  • https://doi.org/10.1016/S1470-2045(18)30192-XDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-357715URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. Methods: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. Findings: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. Interpretation: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. Funding: ELN Foundation and France National Cancer Institute.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Richter, JohanSkåne University Hospital,Skane Univ Hosp, Dept Haematol Oncol & Radiat Phys, Lund, Sweden(Swepub:lu)med-jri (författare)
  • Guilhot, JoellePoitiers University Hospital,Ctr Hosp Univ CHU Poitiers, Ctr Invest Clin 1402, INSERM, Poitiers, France (författare)
  • Gruber, Franz X.University Hospital of North Norway,Univ Hosp North Norway, Dept Haematol, Tromso, Norway (författare)
  • Hjorth-Hansen, HenrikSt. Olav’s University Hospital,St Olavs Hosp, Dept Haematol, Trondheim, Norway (författare)
  • Almeida, AntonioInstituto Português de Oncologia do Porto Francisco Gentil (IPO),Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal (författare)
  • Janssen, Jeroen J.W.M.Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands,Masaryk Univ, Dept Internal Med Haematol & Oncol, Brno, Czech Republic;Univ Hosp Brno, Brno, Czech Republic,Masaryk University,University Hospital Brno (författare)
  • Mayer, JiriMasaryk University,University Hospital Brno (författare)
  • Koskenvesa, PerttuHelsinki University Central Hospital,University of Helsinki,Univ Helsinki, Haematol Res Unit Helsinki, Helsinki, Finland;Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland (författare)
  • Panayiotidis, PanayiotisNational and Kapodistrian University of Athens,Univ Athens, Dept Internal Med 1, Laikon Gen Hosp, Athens, Greece (författare)
  • Olsson-Strömberg, UllaUppsala universitet,Hematologi,Uppsala University Hospital(Swepub:uu)ulols170 (författare)
  • Martinez-Lopez, Joaquin12 de Octubre University Hospital,Univ Complutense Madrid, Hosp Univ Octubre 12, Ctr Nacl Invest Oncol, Ctr Invest Biomed Red Canc, Madrid, Spain (författare)
  • Rousselot, PhilippeVersailles Saint-Quentin-en-Yvelines University,Univ Paris Saclay, Dept Haematol & Oncol, Univ Versailles St Quentin En Yvelines, Ctr Hosp Versailles,Inserm,Unite Mixte Rech 1173, Le Chesnay, France (författare)
  • Vestergaard, HanneOdense University Hospital,Odense Univ Hosp, Dept Haematol, Odense, Denmark (författare)
  • Ehrencrona, HansLund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Off Med Serv, Dept Clin Genet & Pathol, Lab Med, Lund, Sweden;Lund Univ, Div Clin Genet, Lund, Sweden(Swepub:lu)med-hen (författare)
  • Kairisto, VeliTurku University Hospital,Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland;Turku Univ, Cent Hosp, Dept Genet, Turku, Finland (författare)
  • Machová Poláková, KaterinaInstitute of Hematology and Blood Transfusion, Prauge,Inst Hematol & Blood Transfus, Prague, Czech Republic (författare)
  • Müller, Martin C.Institute for Hematology and Oncology (IHO),Inst Hematol & Oncol, Mannheim, Germany (författare)
  • Mustjoki, SatuUniversity of Helsinki,Helsinki University Central Hospital,Univ Helsinki, Haematol Res Unit Helsinki, Helsinki, Finland;Univ Helsinki, Dept Clin Chem & Haematol, Helsinki, Finland;Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland (författare)
  • Berger, Marc G.University of Auvergne,CHU Estaing, Hematol Biol & Equipe Accueil Hemopaties Chron He, Clermont Ferrand, France;Univ Clermont Auvergne, Clermont Ferrand, France (författare)
  • Fabarius, AliceHeidelberg University,Heidelberg Univ, Dept Haematol & Oncol, Univ Hosp Mannheim, Mannheim, Germany (författare)
  • Hofmann, Wolf KarstenHeidelberg University,Heidelberg Univ, Dept Haematol & Oncol, Univ Hosp Mannheim, Mannheim, Germany (författare)
  • Hochhaus, AndreasUniversitätsklinikum Jena,Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany (författare)
  • Pfirrmann, MarkusLudwig-Maximilian University of Munich,Ludwig Maximilians Univ Munchen, Inst Med Informat Verarbeitung Biometrie & Epidem, Munich, Germany (författare)
  • Mahon, Francois XavierUniversity of Bordeaux,Univ Bordeaux, Bergonie Canc Inst, INSERM, Unit 916, Bordeaux, France (författare)
  • Heidelberg UniversityHeidelberg Univ, Dept Haematol & Oncol, Univ Hosp Mannheim, Mannheim, Germany (creator_code:org_t)
  • EURO-SKI investigators

Sammanhörande titlar

  • Ingår i:The Lancet Oncology: Elsevier19:6, s. 747-7571470-20451474-5488

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy